Valneva SE (VALN) Operating Margin (2021 - 2026)
Valneva SE (VALN) posted Operating Margin of 76.68% for Q1 2026, down 5.0% sequentially from 73.03% in Q4 2025, and down 6457.0% YoY from 1.21% in Q1 2025.
Powered by 
Analysis
Valneva SE (VALN) Operating Margin (2021 - 2026) Analysis & Trends
Valneva SE has reported Operating Margin for 6 years, with the latest figure at 76.68% in Q1 2026.
- Quarterly Operating Margin fell 6457.0% year-over-year to 76.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 72.05% (down 3810.0% YoY) and the FY2025 annual result came in at 51.97%, down 6013.0% from the prior year.
- Operating Margin declined to 76.68% in Q1 2026 per VALN's latest filing, from 73.03% in the prior quarter.
- Over five years, Operating Margin peaked at 208.25% in Q1 2024 and troughed at 184.92% in Q2 2022.
- A 5-year average of 43.93% and a median of 50.58% in 2022 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2025: Operating Margin surged 73725 bps in 2022, then tumbled 22036 bps in 2025.
- Over 5 years, Operating Margin stood at 50.58% in 2022, then decreased by 18 bps to 59.45% in 2023, then jumped by 31 bps to 41.11% in 2024, then slumped by 78 bps to 73.03% in 2025, then fell by 5 bps to 76.68% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 76.68%, 73.03%, and 169.96% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | -74.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -74.95% |
| Mar 31, 2026 | -76.68% |
| Dec 31, 2025 | -58.96% |
| Sep 30, 2025 | -126.20% |
| Jun 30, 2025 | -22.49% |
| Mar 31, 2025 | -12.11% |
| Dec 31, 2024 | -39.45% |
| Sep 30, 2024 | -27.17% |
| Jun 30, 2024 | -56.61% |
| Mar 31, 2024 | 208.25% |
| Dec 31, 2023 | -59.45% |
| Sep 30, 2023 | -58.35% |
| Jun 30, 2023 | -45.71% |
| Mar 31, 2023 | -49.46% |
| Dec 31, 2022 | -50.58% |
| Sep 30, 2022 | 59.56% |
| Jun 30, 2022 | -184.92% |
| Mar 31, 2022 | -84.32% |
| Dec 31, 2021 | 63.33% |
| Sep 30, 2021 | -677.70% |